![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
M Teitler, S Leonhardt, EL Weisberg and BJ Hoffman
Department of Pharmacology and Toxicology, Albany Medical College, New York 12208.
Evidence has accumulated indicating that the radioactive hallucinogens 4-bromo-[3H](2,5-dimethoxy)phenylisopropylamine ([3H]DOB) and 4- [125I]iodo-(2,5-dimethoxy)phenylisopropylamine ([125I]DOI) label an agonist high affinity state of the 5-hydroxytryptamine2 (5HT2) receptor and [3H]ketanserin labels both agonist high and low affinity states. Recently, an alternative hypothesis has been put forward proposing that the radioactive hallucinogens are labeling a 5HT2 receptor subtype distinct from the receptor labeled by [3H]ketanserin. In order to provide definitive evidence as to which of these hypotheses is correct, the rat 5HT2 receptor gene was transfected into NIH-3T3 (mammalian fibroblast) cells and COS (green monkey kidney) cells. Neither nontransfected cell type expresses 5HT2 receptors; the transfected cells expressed high affinity binding sites for both [125I] DOI (KD = 0.8 nM and Bmax = 363 fmol/mg in NIH-3T3 cells; KD = 0.2 nM and Bmax = 26 fmol/mg in COS cells) and [3H]ketanserin (KD = 0.4 nM and Bmax = 5034 fmol/mg in NIH-3T3 cells; KD = 1.0 nM and Bmax = 432 fmol/mg in COS cells). The affinities of agonists and antagonists for the [125I]DOI-labeled receptor were significantly higher than for the [3H]ketanserin-labeled receptor. The affinities of agonists and antagonists for these binding sites were essentially identical to their affinities for the sites radiolabeled by these radioligands in mammalian brain homogenates. The [125I]DOI binding was guanyl nucleotide sensitive, indicating a coupling to a GTP-binding protein. These data indicate that the 5HT2 receptor gene product contains both the guanyl nucleotide-sensitive [125I]DOI binding site and the [3H]ketanserin binding site. Therefore, these data indicate that the 5HT2 receptor gene product can produce a high affinity binding site for the phenylisopropylamine hallucinogen agonists as well as for the 5HT2 receptor antagonists. These results strongly support the two-state hypothesis for the 5HT2 receptor and do not support the multiple 5HT2 receptor subtype hypothesis.
This article has been cited by other articles:
|
|
 |
|
  J. F. Lopez-Gimenez, M. Villazon, J. Brea, M. I. Loza, J. M. Palacios, G. Mengod, and M. T. Vilaro Multiple Conformations of Native and Recombinant Human 5-Hydroxytryptamine2A Receptors Are Labeled by Agonists and Discriminated by Antagonists Mol. Pharmacol., October 1, 2001; 60(4): 690 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. L. Roth, D. L. Willins, K. Kristiansen, and W. K. Kroeze Activation is Hallucinogenic and Antagonism is Therapeutic: Role of 5-HT2A Receptors in Atypical Antipsychotic Drug Actions Neuroscientist, July 1, 1999; 5(4): 254 - 262. [Abstract] [PDF]
|
|
|
|
 |
|
 C. T. Egan, K. Herrick-Davis, and M. Teitler Creation of a Constitutively Activated State of the 5-Hydroxytryptamine2A Receptor by Site-Directed Mutagenesis: Inverse Agonist Activity of Antipsychotic Drugs J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 85 - 90. [Abstract] [Full Text]
|
|
|
|
|
|
A. Kulikov, S. Aguerre, O. Berton, A. Ramos, P. Mormede, and F. Chaouloff Central Serotonergic Systems in the Spontaneously Hypertensive and Lewis Rat Strains that Differ in the Elevated Plus-Maze Test of Anxiety J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 775 - 784. [Abstract] [Full Text]
|
|
|
|
|
|
B. L. Roth, M. S. Choudhary, N. Khan, and A. Z. Uluer High-affinity Agonist Binding Is Not Sufficient for Agonist Efficacy at 5-Hydroxytryptamine2A Receptors: Evidence in Favor of a Modified Ternary Complex Model J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 576 - 583. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
